Partnerships Picks For GeNeuro’s MS Antibody
GeNeuro’s CEO And His Mission To Bring Anti-HERV Benefits To MS Patients
Executive Summary
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.
You may also be interested in...
GeNeuro, Servier 'Disappointed' With Mid-Way Phase IIb Multiple Sclerosis Study
GeNeuro and partner Servier voiced disappointment over results seen midway through a Phase IIb trial studying a potential cause of multiple sclerosis - but insisted the trial will continue for the final 6 months.
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.